Phase II trial of efatutazone shows challenge of matching treatment to population

(University of Colorado Denver) Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported today at the American Association for Cancer Research Annual Meeting 2014. While efatutazone did not improve the efficacy of erlotinib in this trial, researchers hope lessons from the trial will allow them to make better future use of the drug or other drugs in its class.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news